Cargando…

Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors

Ovarian carcinoma is a heterogeneous disease with distinct molecular and histological profiles, ranging from low grade atypia to highly aggressive tumors associated with a poor prognosis. In the present study, glycosphingolipids were isolated from human high-grade serous ovarian carcinoma, whereby t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barone, Angela, Linder, Anna, Mateoiu, Constantina, Köster Larsen, Rasmus, Blixt, Ola, Teneberg, Susann, Sundfeldt, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539041/
https://www.ncbi.nlm.nih.gov/pubmed/33072588
http://dx.doi.org/10.3389/fonc.2020.561888
_version_ 1783590984696725504
author Barone, Angela
Linder, Anna
Mateoiu, Constantina
Köster Larsen, Rasmus
Blixt, Ola
Teneberg, Susann
Sundfeldt, Karin
author_facet Barone, Angela
Linder, Anna
Mateoiu, Constantina
Köster Larsen, Rasmus
Blixt, Ola
Teneberg, Susann
Sundfeldt, Karin
author_sort Barone, Angela
collection PubMed
description Ovarian carcinoma is a heterogeneous disease with distinct molecular and histological profiles, ranging from low grade atypia to highly aggressive tumors associated with a poor prognosis. In the present study, glycosphingolipids were isolated from human high-grade serous ovarian carcinoma, whereby the novel stem cell marker Sialyl-lactotetra (S-Lc(4)) was characterized in two out of three cases. The presence and level of S-Lc(4) was further evaluated immunohistochemically in a cohort of patients with ovarian tumors ranging from benign lesions to high grade serous carcinoma (n = 478). Its expression was assessed in association with tumor grade, stage, histology, and survival. The data showed that S-Lc(4) is most common and highly expressed in borderline type tumors and carcinomas with low levels of aggressiveness, such as mucinous, endometrioid, and low grade serous. Accordingly, S-Lc(4)-positivity was associated with better disease-free survival. The expression of S-Lc(4) was seemingly associated with lineage continuity and could be traced from premalignant lesions to carcinoma, suggesting inheritance by a stem cell lineage that gives rise to generally indolent tumors.
format Online
Article
Text
id pubmed-7539041
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75390412020-10-15 Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors Barone, Angela Linder, Anna Mateoiu, Constantina Köster Larsen, Rasmus Blixt, Ola Teneberg, Susann Sundfeldt, Karin Front Oncol Oncology Ovarian carcinoma is a heterogeneous disease with distinct molecular and histological profiles, ranging from low grade atypia to highly aggressive tumors associated with a poor prognosis. In the present study, glycosphingolipids were isolated from human high-grade serous ovarian carcinoma, whereby the novel stem cell marker Sialyl-lactotetra (S-Lc(4)) was characterized in two out of three cases. The presence and level of S-Lc(4) was further evaluated immunohistochemically in a cohort of patients with ovarian tumors ranging from benign lesions to high grade serous carcinoma (n = 478). Its expression was assessed in association with tumor grade, stage, histology, and survival. The data showed that S-Lc(4) is most common and highly expressed in borderline type tumors and carcinomas with low levels of aggressiveness, such as mucinous, endometrioid, and low grade serous. Accordingly, S-Lc(4)-positivity was associated with better disease-free survival. The expression of S-Lc(4) was seemingly associated with lineage continuity and could be traced from premalignant lesions to carcinoma, suggesting inheritance by a stem cell lineage that gives rise to generally indolent tumors. Frontiers Media S.A. 2020-09-23 /pmc/articles/PMC7539041/ /pubmed/33072588 http://dx.doi.org/10.3389/fonc.2020.561888 Text en Copyright © 2020 Barone, Linder, Mateoiu, Köster Larsen, Blixt, Teneberg and Sundfeldt. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Barone, Angela
Linder, Anna
Mateoiu, Constantina
Köster Larsen, Rasmus
Blixt, Ola
Teneberg, Susann
Sundfeldt, Karin
Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors
title Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors
title_full Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors
title_fullStr Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors
title_full_unstemmed Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors
title_short Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors
title_sort evaluation of sialyl-lactotetra as a marker for epithelial ovarian tumors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539041/
https://www.ncbi.nlm.nih.gov/pubmed/33072588
http://dx.doi.org/10.3389/fonc.2020.561888
work_keys_str_mv AT baroneangela evaluationofsialyllactotetraasamarkerforepithelialovariantumors
AT linderanna evaluationofsialyllactotetraasamarkerforepithelialovariantumors
AT mateoiuconstantina evaluationofsialyllactotetraasamarkerforepithelialovariantumors
AT kosterlarsenrasmus evaluationofsialyllactotetraasamarkerforepithelialovariantumors
AT blixtola evaluationofsialyllactotetraasamarkerforepithelialovariantumors
AT tenebergsusann evaluationofsialyllactotetraasamarkerforepithelialovariantumors
AT sundfeldtkarin evaluationofsialyllactotetraasamarkerforepithelialovariantumors